The present application relates to compositions and methods for treating a proliferative disorder by administering to a subject a pharmaceutical composition of a dual kinase inhibitor metabolite. Catecholic butane metabolites can serve as dual kinase inhibitors for purposes of methods described herein.

In one embodiment, the present application discloses a catalyst composition comprising: a) a reaction solvent or a reaction medium; b) organometallic nanoparticles comprising: i) a nanoparticle (NP) catalyst, prepared by a reduction of an iron salt in an organic solvent, wherein the catalyst comprises at least one other metal selected from the group consisting of Pd, Pt, Au, Ni, Co, Cu, Mn, Rh, Ir, Ru and Os or mixtures thereof; c) a ligand; and d) a surfactant; wherein the metal or mixtures thereof is present in less than or equal to 50,000 ppm relative to the iron salt.

A method for synthesizing (R)-(−)-1-((S)-2-diphosphino ferrocene)-ethyl-diphosphine by: 1) adding vinylferrocene, a chiral catalyst, and toluene to a first drying reactor; adding a phosphorus-hydrogen compound to the first drying reactor and allowing reactants in the first drying reactor to react; cooling the first drying reactor; adding water dropwise to the first drying reactor; extracting, drying, and recrystallizing a product to yield (R)-1-ferrocenylethyl-diphosphine; 2) adding the (R)-1-ferrocenylethyl-diphosphine and ether to a second drying reactor; adding a hexane solution including diethylzinc to the second drying reactor and allowing reactants in the second drying reactor to react; adding a phosphorus-chlorine compound dropwise to the second drying reactor, and heating and refluxing the reaction mixture in the second drying reactor; adding water to quench the reaction mixture in the second drying reactor; and extracting, drying, and recrystallizing the reaction mixture.

The present invention relates to a process for producing flame-retarded polyurethane foams, in particular flexible polyurethane foams, using halogen-free flame retardants, wherein the resulting flame-retarded polyurethane foams exhibit low emission values coupled with good mechanical properties. The present invention further relates to halogen-free flame retardants.

The present invention relates to a process for producing flame-retarded polyurethane foams, in particular flexible polyurethane foams, using halogen-free flame retardants, wherein the resulting flame-retarded polyurethane foams exhibit low emission values coupled with good mechanical properties. The present invention further relates to halogen-free flame retardants.

Provided are a near-infrared-ray-absorbing composition having strong near-infrared shielding properties when a cured film is produced, a near-infrared-ray cut filter, a manufacturing method therefor, a camera module, and a manufacturing method therefor. The near-infrared-ray-absorbing composition includes a copper complex obtained by reacting a compound (A) having at least two coordination sites with a copper component.

Provided are a near-infrared-ray-absorbing composition having strong near-infrared shielding properties when a cured film is produced, a near-infrared-ray cut filter, a manufacturing method therefor, a camera module, and a manufacturing method therefor. The near-infrared-ray-absorbing composition includes a copper complex obtained by reacting a compound (A) having at least two coordination sites with a copper component.

The present invention provides dioxetane-based chemiluminescence probes, more specifically fluorophore-tethered dioxetane-based chemiluminescence probes and compositions thereof. The chemiluminescence probes disclosed are useful for both diagnostics and in vivo imaging.

The present invention provides dioxetane-based chemiluminescence probes, more specifically fluorophore-tethered dioxetane-based chemiluminescence probes and compositions thereof. The chemiluminescence probes disclosed are useful for both diagnostics and in vivo imaging.

Disclosed are small molecule PLK inhibitors that can target the polo box domain (PBD). Inhibitors can have an atomic mass of about 1000 Da or less and a general structure of

##STR00001##

For instance, the inhibitors can include an alkyl benzamido benzoic acid core structure.